Lawsuit Overview - A class action lawsuit has been filed against Metagenomi Inc on behalf of investors who acquired its securities between February 9 2024 and May 1 2024 [1] - Investors have until November 25 2024 to apply to be appointed as lead plaintiff in the lawsuit [1] IPO and Stock Performance - Metagenomi conducted its IPO on February 12 2024 selling approximately 6 25 million shares at $15 per share [1] - On May 1 2024 Metagenomi announced the termination of its collaboration with Moderna leading to a 12 4% decline in share price from $7 04 to $6 17 [1] Allegations in the Lawsuit - The lawsuit alleges that Metagenomi's IPO registration statements were false and/or materially misleading [2] - Metagenomi represented itself as having a long-standing business relationship with Moderna but the collaboration was terminated shortly after the IPO [2] Law Firm Information - Kirby McInerney LLP is handling the lawsuit and has a history of recovering billions of dollars for shareholders in securities litigation [3]

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=108714&from=4 CLASS PERIOD: This lawsuit is on beha ...

SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who purchased stock pursuant to and/or traceable to Metagenomi Inc.'s (NASDAQ: MGX) registration statement for the initial public offering (IPO) held between February 9 and 13, 2024. Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. For more information, ...

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=108485&from=3 CLASS PERIOD: This lawsuit is on ...

PHILADELPHIA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against Metagenomi Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) on behalf of purchasers of Metagenomi securities between February 6, 2024 and September 26, 2024, inclusive (the "Class Period"). Investors that suffered losses from METAGENOMI (NASDAQ: MGX) investments can follow the link below for more information regarding the lawsuit: CLICK HERE to learn more abo ...

Poster presentation highlights SMART adenine base editors (ABEs) small enough to be packaged into a single adeno-associated virus (AAV) Data demonstrate compact SMART system optimizations allowing for therapeutically-relevant genome editing EMERYVILLE, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today presented a poster titled "Engineering ...

NEW YORK, Oct. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=107873&from=4 CLASS PERIOD: This lawsuit is on beha ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Metagenomi To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Metagenomi between February 9, 2024 and September 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247- 4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 11, 202 ...

NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") announces that a federal securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of persons and entities that purchased or otherwise acquired Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) securities between February 6, 2024 and September 26, 2024, inclusive (the "Class Period"). CLICK HERE TO PROVIDE CONTACT I ...

NEW YORK, Oct. 10, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=107512&from=4 CLASS PERIOD: This lawsuit is on beha ...